Cargando…
The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis
BACKGROUND/AIM: Patients with HBV-related decompensated cirrhosis (HBV-DeCi) should be treated with potent nucleos(t)ide analogues (NA)[entecavir (ETV) or tenofovir (TDF)]. The aim was the evaluation of safety and efficacy in terms of changes in liver disease course in HBV-DeCi patients treated with...
Autores principales: | Cholongitas, Evangelos, Papatheodoridis, George V., Goulis, John, Vlachogiannakos, John, Karatapanis, Stylianos, Ketikoglou, John, Vasiliadis, Themistoklis, Kontos, George, Karlaftis, Anastasios, Akriviadis, Evangelos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hellenic Society of Gastroenterology
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289983/ https://www.ncbi.nlm.nih.gov/pubmed/25608681 |
Ejemplares similares
-
Nucleos(t)ide analogues for the prevention of hepatitis B recurrence after liver transplantation do not affect serum phosphorus levels
por: Sinakos, Emmanouil, et al.
Publicado: (2016) -
The significance of C-reactive protein to albumin ratio in patients with decompensated cirrhosis
por: Oikonomou, Theodora, et al.
Publicado: (2020) -
Clinical impact of microbiome in patients with decompensated cirrhosis
por: Oikonomou, Theodora, et al.
Publicado: (2018) -
Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs
por: Siakavellas, Spyros, et al.
Publicado: (2021) -
Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview
por: Tampaki, Maria, et al.
Publicado: (2023)